Media headlines about Kamada (NASDAQ:KMDA) have been trending somewhat positive on Thursday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Kamada earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.6270211952708 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Kamada from a “hold” rating to a “strong sell” rating in a report on Thursday, November 16th. ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. Two investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $8.50.
Shares of Kamada (NASDAQ:KMDA) traded up $0.15 during trading hours on Thursday, reaching $4.50. 55,900 shares of the company’s stock traded hands, compared to its average volume of 68,413. The company has a quick ratio of 2.73, a current ratio of 3.71 and a debt-to-equity ratio of 0.02. Kamada has a 1 year low of $3.75 and a 1 year high of $8.61.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Kamada (KMDA) Stock Price” was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.truebluetribune.com/2017/12/14/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-kamada-kmda-stock-price.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.